

CLAIMS

1. A method of treating BPH in a subject in need of such treatment which method comprises administering to said subject an effective amount of a
5 combination of (A) atorvastatin or a pharmaceutically acceptable derivative thereof and (B) an α_1 -adrenergic receptor antagonist, or a pharmaceutically acceptable derivative thereof.
3. The method of claim 1 wherein (A) and (B) are administered
10 simultaneously, sequentially or separately.
4. The method of claim 1, wherein (B) is selected from terazosin, doxazosin, prazosin, bunazosin, alfuzosin, naftopidil, tamsulosin, silodosin, 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-
15 pyridyl)quinazoline, 5-cyclopropyl-7-methoxy-2-(2-morpholin-4-ylmethyl-7,8-dihydro[1,6]-naphthyridin-6(5H)-yl)-4(3H)-quinazolinone, or a pharmaceutically acceptable derivative thereof.
5. The method of claim 4, wherein (B) is doxazosin or a pharmaceutically
20 acceptable derivative thereof.
6. The method of claim 4, wherein (B) is 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline
25 or a pharmaceutically acceptable derivative thereof.
7. The method of claim 4, wherein (B) is 5-cyclopropyl-7-methoxy-2-(2-morpholin-4-ylmethyl-7,8-dihydro[1,6]-naphthyridin-6(5H)-yl)-4(3H)-
quinazolinone, or a pharmaceutically acceptable derivative thereof.
- 30 8. A pharmaceutical composition comprising (A) atorvastatin, or a pharmaceutically acceptable derivative thereof, and (B) doxazosin, or a pharmaceutically acceptable derivative thereof.

9. A pharmaceutical composition comprising (A) atorvastatin or a pharmaceutically acceptable derivative thereof and (B) 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline or a pharmaceutically acceptable derivative thereof.
- 5
10. A pharmaceutical composition comprising (A) atorvastatin or a pharmaceutically acceptable derivative thereof and (B) 5-cyclopropyl-7-methoxy-2-(2-morpholin-4-ylmethyl-7,8-dihydro[1,6]-naphthyridin-6(5H)-yl)-4(3H)-quinazolinone or a pharmaceutically acceptable derivative thereof.
- 10
11. A pharmaceutical composition comprising, separately or together, (A) atorvastatin or a pharmaceutically acceptable derivative thereof and (B) doxazosin or a pharmaceutically acceptable derivative thereof, for simultaneous, sequential or separate administration in the treatment of BPH.
- 15
12. A pharmaceutical composition comprising, separately or together, (A) atorvastatin or a pharmaceutically acceptable derivative thereof and (B) 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline or a pharmaceutically acceptable derivative thereof,
- 20 for simultaneous, sequential or separate administration in the treatment of BPH.
13. A pharmaceutical composition comprising, separately or together, (A) atorvastatin or a pharmaceutically acceptable derivative thereof and (B) 5-cyclopropyl-7-methoxy-2-(2-morpholin-4-ylmethyl-7,8-dihydro[1,6]-naphthyridin-6(5H)-yl)-4(3H)-quinazolinone or a pharmaceutically acceptable derivative thereof, for simultaneous, sequential or separate administration in the treatment of BPH.
- 25
14. A pharmaceutical composition according to any one of claims 8 to 13,
- 30 further comprising a pharmaceutically acceptable carrier.